Rapid antibiotic monitoring exposes wide dosing variability in critical illness
Critically ill patients rarely handle antibiotics in a predictable way. Renal clearance can shift quickly, volume of distribution can expand, and standard dosing may miss the concentration needed to suppress pathogens without pushing patients toward toxicity. In that setting, a laboratory method that can measure several drugs at once is not just a technical convenience; it becomes part of the effort to keep therapy aligned with changing physiology.
This study built a multiplex LC-MS/MS platform for simultaneous measurement of eight antibiotics in human serum: vancomycin, meropenem, linezolid, voriconazole, sulfamethoxazole, trimethoprim, piperacillin, and cefoperazone. Investigators then applied the assay to therapeutic drug monitoring in critically ill patients and explored which clinical variables tracked with serum concentrations. The work sits at the intersection of clinical pharmacology and bedside critical care, where underexposure can fail to control infection and overexposure can add avoidable harm.
One result stood out immediately. Target attainment ranged from 22.2% to 70.4% across the monitored agents.
A validated assay built for the pace of intensive care
The analytical method used protein precipitation and was validated in line with FDA and EMA expectations. Performance was strong across the range of interest: linearity exceeded r² > 0.98, recovery ranged from 63.4% to 110.6%, and matrix effects remained minimal at 89.2% to 105.2%. Those figures matter because critically ill serum can be chemically messy, and a dependable assay has to remain accurate despite that complexity. If the platform drifts or becomes distorted by the sample matrix, therapeutic drug monitoring loses the precision clinicians depend on when dose changes are being made around the clock.
The platform was used on 522 serum samples from critically ill patients undergoing TDM. From a practical standpoint, that sample volume suggests the method was not merely a proof of concept on a handful of specimens. It was taken into the clinical workflow and used to generate exposure data across a real ICU population, where rapid reassessment is often needed because organ function changes faster than prescribing intervals.
Renal function, dose, sex, and anemia tracked with exposure
Among the clinical variables examined, creatinine clearance had a clear inverse relationship with concentrations of vancomycin, meropenem, linezolid, and piperacillin. In pharmacologic terms, faster renal clearance can strip these drugs from the circulation before they reach or maintain desired levels, especially when dosing is not adjusted promptly. In critical illness, that can translate into a patient who looks adequately covered on paper but is actually drifting below therapeutic exposure at the bedside.
Daily dose moved in the opposite direction for several agents. Higher daily dosing positively influenced levels of vancomycin, meropenem, sulfamethoxazole, and trimethoprim. The relationship is expected, but it remains clinically important because the direction and size of dose-response can vary when renal handling, distribution, and illness severity are changing at the same time. Dose escalation alone is not a substitute for monitoring, but the data support why repeated measurement is needed before assuming a regimen is adequate.
Sex significantly affected sulfamethoxazole concentrations. Red blood cell count was inversely correlated with exposure to meropenem and trimethoprim. Those associations do not automatically prove a causal mechanism, yet they point to the possibility that hematologic status and sex-linked factors may influence distribution or measured exposure in ways that routine dosing misses. In the ICU, anemia is common, plasma composition is unstable, and measured concentrations may reflect more than kidney function alone.
Why simultaneous measurement changes the monitoring model
The value of this assay lies in breadth as much as speed. ICU patients frequently receive combinations of broad-spectrum antibiotics, and separate assays for each drug can slow the clinical response or make broad surveillance impractical. A single multiplex platform can compress that workflow, allowing multiple agents to be checked in the same analytic pass while preserving the ability to respond to an individual patient’s concentration profile.
That matters most when the therapeutic window is narrow or when treatment failure would carry a high price. Vancomycin and meropenem are standard examples in intensive care, but the inclusion of linezolid, voriconazole, piperacillin, cefoperazone, sulfamethoxazole, and trimethoprim broadens the reach of the platform into infections where underdosing can be just as consequential. The study does not claim that one dosing formula fits all. It shows the opposite: exposure varied enough that empiric dosing alone was often insufficient.
Clinical application points toward individualized dosing, but not a final dosing rule
The data support therapeutic drug monitoring as a practical route toward individualized antibiotic dosing in critically ill patients. Renal function emerged as a major determinant, dose remained a strong driver of exposure, and sex and anemia-related variables also entered the picture for selected drugs. That combination of findings fits the biology of critical illness, where altered clearance and altered distribution can work together to make usual regimens unreliable.
The study’s authors frame these analyses as exploratory, and that restraint is appropriate. The correlations identify candidate determinants of exposure, but they do not by themselves establish a dosing algorithm that can be copied into all intensive care units. No single pharmacokinetic relationship will erase the effects of organ failure, fluctuating fluid balance, or the day-to-day turnover in a critically ill patient’s physiology. The more immediate contribution is methodological: the assay makes repeated, simultaneous antibiotic monitoring feasible, and the exposure data show why that capability is needed.
A final practical point comes from the target attainment range itself. When only a minority to a modest majority of samples reach target, the gap between prescribed dose and effective exposure is too large to ignore. In a population where resistance, toxicity, and treatment failure all carry serious consequences, that gap becomes a reason to measure rather than assume.
The study was approved by the Ethics Committee of Hunan University of Medicine General Hospital. Future work will need to determine whether these exposure relationships can be turned into validated, drug-specific dosing strategies that improve outcomes rather than simply describe variability more precisely.